0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Clinical and Antibody Responses After Influenza Immunization in Systemic Lupus Erythematosus

JAMES S. LOUIE, M.D., F.A.C.P.; KENNETH M. NIES, M.D., F.A.C.P.; KENT T. SHOJI, M.D.; RONALD C. FRABACK, M.D.; CHRISTINE ABRASS, M.D.; WAYNE BORDER, M.D.; JAMES D. CHERRY, M.D.; and DAVID IMAGAWA, Ph.D.
[+] Article and Author Information

Grant support: in part by an Institutional Grant from the Arthritis Foundation, Southern California Chapter; Contract #200-76-0676 from the Department of Health, Education, and Welfare, Center for Disease Control, Atlanta, Georgia; and Contract #1-A1-62510 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

▸Requests for reprints should be addressed to James S. Louie, M.D.; Division of Rheumatology, Harbor General Hospital, 1000 West Carson St.; Torrance, CA 90509.


Torrance and Los Angeles, California


© 1978 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1978;88(6):790-792. doi:10.7326/0003-4819-88-6-790
Text Size: A A A

After immunization with A/New Jersey/76 and A/Victoria/75 influenza vaccines, 11 patients with systemic lupus erythematosus were serially evaluated for changes in disease activity, serologic abnormalities, and their capability to generate specific antibodies. One patient, with active disease, developed a diffuse, proliferative glomerulonephritis. None of the other patients or control subjects had significant local or systemic side effects. Significant levels of antibodies were generated to A/New Jersey/76 in eight of the 11 patients and in seven of eight control subjects and to A/Victoria/75 in seven of 11 patients and five of eight control subjects. The geometric mean responses of both total and IgG antibodies to each viral antigen were no different in patients with systemic lupus erythematosus than in control subjects. In patients with stable systemic lupus erythematosus, immunization with killed influenza viral vaccine appears to be safe and effective.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)